| Similar Articles |
|---|
 |
BusinessWeek
March 7, 2005
Catherine Arnst |
A Most Victorious Vaccine A review of Jeffrey Kluger's book Splendid Solution: Jonas Salk and the Conquest of Polio, which chronicles polio epidemics in the first half of the 20th century, and scientific efforts by Salk and his colleagues to create a vaccine quickly.   |
BusinessWeek
June 28, 2004
Amy Barrett |
Jonas Salk: He Put An End To Polio In the '50s, Dr. Jonas Salk moved with lightning speed to develop and test a vaccine for polio. |
The Motley Fool
September 25, 2007
Brian Orelli |
Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note. |
Chemistry World
January 29, 2015
Matthew Gunther |
Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study. |
BusinessWeek
November 18, 2010
Jason Gale |
Bill Gates' Latest Challenge: Polio Bill Gates is brokering deals with drugmakers to make cheaper vaccines available. |
Wired
January 2003
Richard Martin |
Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine. |
BusinessWeek
October 20, 2003
Gene G. Marcial |
How Immune Response Targets AIDS Immune Response's Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. A look at the company's situation and its stock. |
Popular Mechanics
September 2006
Ben Harder |
Seeking Immunity Pathogens like West Nile virus show no respect for borders. But a new class of vaccines may soon keep them in check. |
Chemistry World
September 3, 2009
Sarah Houlton |
New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine. |
The Motley Fool
November 13, 2008
Brian Orelli |
Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men. |
The Motley Fool
September 24, 2009
Brian Orelli |
Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share. |
| AskMen.com |
Vaccine Helps Prevent HIV For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. |
The Motley Fool
November 19, 2009
Brian Orelli |
Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed. |
| AskMen.com |
1 Million Swine Flu Cases? Swine flu has infected as many as 1 million Americans, U.S. health officials said Thursday, adding that 6 percent or more of some urban populations are infected. |
Chemistry World
July 8, 2010
Sarah Houlton |
Antibodies spark HIV vaccine hopes These cross-reactive broadly neutralising antibodies bound to and neutralised more than 90 per cent of the HIV strains they were tested against. |
Chemistry World
October 9, 2013
Phillip Broadwith |
GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months. |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
American Family Physician
January 15, 2004 |
Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc. |
Chemistry World
October 23, 2014
Rebecca Trager |
US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
The Motley Fool
June 26, 2008
Brian Lawler |
Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay. |
Chemistry World
December 3, 2014
Maria Burke |
Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline. |
The Motley Fool
August 20, 2007
Brian Orelli |
Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign. |
Bio-IT World
June 15, 2003
Malorye Branca |
A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery? |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
The Motley Fool
October 19, 2004
Rich Duprey |
Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void. |
Chemistry World
February 9, 2007
Victoria Gill |
Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo. |
